LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis

This study is measuring levels of two brain proteins — LRFN5 and OLFM4 — in three groups: people with methamphetamine use disorder, people who have developed methamphetamine-induced psychosis (a condition where meth use causes hallucinations and delusions similar to schizophrenia), and healthy volunteers. The goal is to understand the biological changes involved in meth-related brain disorders. **You may be eligible if:** - You are between 18 and 65 years old - You are in one of these groups: diagnosed with methamphetamine use disorder (MUD), diagnosed with methamphetamine-induced psychosis (MP), OR a healthy volunteer with no psychiatric diagnosis - You have not taken any medication for at least one month prior to the study **You may NOT be eligible if:** - You have high blood pressure, diabetes, kidney disease, rheumatoid arthritis, lupus, or serious cardiac disease - You have a severe neurological condition, an immune or systemic illness, or a primary psychiatric disorder other than the meth-related condition being studied - You have alcohol use disorder Talk to your doctor to see if this trial is right for you.